Our findings throughout AD progression support this hypothesis; hence, a significant increase in PrP in brain EV was uniquely manifested during the preclinical stage of AD, and the presence of PrP in brain EV was reduced to similar levels as in age-matched controls at the initial manifestation of clinical signs. This evidence concerns the gene PRNP and Alzheimer disease.